Plus Therapeutics Reports Q2 Earnings Miss
Plus Therapeutics announced GAAP EPS of -$1.31, missing analyst estimates by $0.45, while reaffirming its full-year financial outlook.
Results for "Plus Therapeutics"
7 stories found
Two Therapeutics Companies Regain Nasdaq Compliance
Plus Therapeutics and XORTX Therapeutics have both announced that they have regained compliance with Nasdaq listing requirements. This ensures their continued listing on the stock exchange.
Plus Therapeutics Beats Q4 EPS and Revenue Estimates
Plus Therapeutics reported a GAAP EPS of -$0.29, beating estimates by $0.01, and revenue of $5.21 million, surpassing expectations by $0.14 million.
Plus Therapeutics Secures Coverage Deal with Elevance Health
Plus Therapeutics announced it has secured a coverage deal with Elevance Health, expanding access to its treatments.
D. Boral Capital Downgrades Plus Therapeutics (PSTV) to Hold
D. Boral Capital has downgraded its rating for Plus Therapeutics (PSTV) to Hold.
Various Companies Report Latest Quarterly Financial Results
A range of companies, including Allarity Therapeutics, Beam Global, and Boot Barn, have released their latest quarterly financial results. These reports detail GAAP EPS, revenue figures, and often include earnings call transcripts or highlights.
Plus Therapeutics Announces Reverse Stock Split
Plus Therapeutics has announced a reverse stock split, a corporate action to reduce the number of its outstanding shares.